ACA
RLMD icon

Avoro Capital Advisors’s Relmada Therapeutics RLMD Stock Holding History

Avoro Capital Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-935,000
Closed -$29.9M – 52
2021
Q2 		$29.9M Sell
935,000
-590,000
-39% -$20.5M 0.52% 30
2021
Q1 		$53.7M Hold
1,525,000
– – 0.93% 23
2020
Q4 		$48.9M Buy
1,525,000
+25,000
+2% +$859K 0.84% 25
2020
Q3 		$56.4M Buy
1,500,000
+75,000
+5% +$2.9M 0.8% 25
2020
Q2 		$63.8M Buy
1,425,000
+275,000
+24% +$11.6M 1.26% 19
2020
Q1 		$39.2M Buy
+1,150,000
New +$46.4M 1.32% 19

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avoro Capital Advisors's RLMD Position: Q3 2021 in Review

Avoro Capital Advisors sold out of Relmada Therapeutics (RLMD) in Q3 2021, closing a stake of 935,000 shares — an estimated $29.9M sold.

Avoro Capital Advisors first reported a position in RLMD in Q1 2020 and held it in 6 quarters. The position peaked at $63.8M in Q2 2020. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2021.

  • Avoro Capital Advisors reported no remaining Relmada Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Avoro Capital Advisors sold 935,000 Relmada Therapeutics shares in Q3 2021, an estimated $29.9M.
  • Avoro Capital Advisors first reported a position in Relmada Therapeutics in Q1 2020 and held it in 6 quarters.
  • Avoro Capital Advisors's Relmada Therapeutics position peaked at $63.8M in Q2 2020.
  • 87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2021.

Based on Avoro Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.